Article Text
Abstract
Parkinson’s disease is a common neurodegenerative condition with a prevalence of about 160/100 000 in Western Europe rising to as high as 2% of the population over 80 years old (Mutch et al. 1986). The disease has a major socio-economic impact. The annual direct cost of care per patient is about £6000, while the indirect costs and the burden of the disease on patients and their carers are incalculable (Findley et al. 2003). Furthermore, a move from home to residential care is associated with an approximately 500% cost increase. Therefore, the management of Parkinson’s disease is likely to prove an increasingly important and challenging aspect of medical practice as the population ages.
Therapeutic strategies have for the large part focused on pharmacological agents, and there has also been an increasing trend towards specialist Parkinson’s disease clinics run by physicians with a specific interest in the disease. Such clinics often provide
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Occurrence, mortality and cost of brain disorders in Denmark: a population-based cohort study
- Present and future drug treatment for Parkinson’s disease
- Economic burden of low physical activity and high sedentary behaviour in Finland
- Economic burden from smoking-related diseases in Thailand
- How do multiple long-term conditions impact on the cost-of-illness in early rheumatoid arthritis?
- Economic burden of tobacco use in Pakistan
- Good-quality social care for people with Parkinson’s disease: a qualitative study
- Excess costs of type 2 diabetes and their sociodemographic and clinical determinants: a cross-sectional study using data from the German Health Interview and Examination Survey for Adults (DEGS1)
- Cost of ambulatory care of diabetes mellitus: a study from north India
- The economic impact of neurological illness on the health and wealth of the nation and of individuals